Reishi (Ganoderma lucidum)
0 of 4human trials measured sleep
Reishi has four randomized controlled human trials — more than most medicinal mushrooms. None of them recorded sleep latency, sleep duration, or sleep quality. Every sleep finding attributed to reishi comes from rodents.
Tang et al. 2005; Collado-Mateo et al. 2015; Pazzi et al. 2020; Mitra et al. 2024
5.4 g/day
the dose in the largest positive human trial — Ganopoly extract at 1,800 mg three times daily, not 1,800 mg per day (Tang 2005)
6 g/day
micro-milled whole reishi used in both fibromyalgia trials; the 2020 placebo-controlled pilot found no significant between-group difference
Rodent only
sleep latency and sleep architecture data exist only in rats and mice, mostly in animals given a sedative first (Chu 2007)
Tang et al. 2005; Collado-Mateo et al. 2015; Pazzi et al. 2020; Mitra et al. 2024
View as image ↗For most people researching reishi for sleep, the practical questions come quickly: does the clinical evidence hold up, what dose was actually tested, and does product form matter? This article answers those questions directly — and the first answer is not the one most consumer content gives.
The short version: reishi has four randomized controlled human trials, and none of them measured sleep. They measured fatigue, physical fitness, mood, and quality of life. Every claim about reishi shortening sleep latency or extending non-REM sleep traces back to rats and mice, usually rats and mice that were given a sedative first. That is a real evidence base, but it is not the evidence base most articles describe. For a broader overview of the mechanisms involved, reishi for sleep: what the research shows covers the full picture. This article stays focused on what was dosed, what was measured, and how to read a product label against that.
For the broader context on what reishi is and its full research profile, the guide to reishi mushroom provides that background.
Key Takeaways
- Four randomized controlled human trials of Ganoderma lucidum have been published, and not one of them included a sleep endpoint — no sleep latency, no sleep duration, no sleep-quality instrument, no polysomnography
- The strongest human trial is Tang et al. (2005): 132 patients with neurasthenia, Ganopoly polysaccharide extract at 1,800 mg three times daily (5,400 mg/day) for 8 weeks, with significant improvements in fatigue and well-being versus placebo
- The widely repeated "1,800 mg per day" dosing figure is a misreading — 1,800 mg was the per-dose amount in Tang 2005, taken three times a day
- The 2020 placebo-controlled fibromyalgia pilot (Pazzi et al.) used 6 g/day of micro-milled whole reishi and found no statistically significant between-group differences; only within-group trends were reported
- Rodent sleep data is real but heavily model-dependent: Chu et al. (2007) found reishi extract had no effect on sleep architecture in normal rats and only worked in rats already given pentobarbital
- A 2023 systematic review of reishi spores did not establish sedative or hypnotic activity, and specifically flagged that high doses raised the cancer antigen CA72-4, recommending caution
- Reishi powder carries a documented hepatotoxicity signal, including one fatal case; this is not a benign supplement to take indefinitely without oversight
What the Human Trials Actually Measured
Reishi is better studied in humans than most medicinal mushrooms. Four randomized controlled trials exist. The problem is subtler than "no evidence": every one of them measured something adjacent to sleep rather than sleep itself.
The Endpoint Gap
Four Randomised Human Trials. Zero Measured Sleep.
Reishi is better studied in humans than most medicinal mushrooms — four randomised controlled trials, three against placebo and one against an active comparator. The problem is subtler than “no evidence”: every one of them measured something other than sleep. Fatigue, fitness, mood, quality of life. Sleep latency, sleep duration and sleep quality were never recorded.
Tang 2005 [1]
Positive132 adults with neurasthenia
Ganopoly extract 1,800 mg × 3/day (5.4 g/day), 8 weeks
Measured: Clinical Global Impression · fatigue VAS · well-being VAS
Found: Fatigue −28.3% vs −20.1% placebo; 51.6% vs 24.6% improved (p = .002)
No sleep endpoint
Collado-Mateo 2015 [4]
Narrow scope64 women with fibromyalgia
6 g/day whole milled reishi, 6 weeks
Measured: Aerobic endurance · lower-body flexibility · velocity
Found: Significant fitness gains (p < .05) vs carob active comparator
No sleep endpoint
Pazzi 2020 [5]
Null resultWomen with fibromyalgia (placebo-controlled pilot)
6 g/day micro-milled carpophores, 6 weeks
Measured: Happiness · depression · life satisfaction · HRQoL
Found: No statistically significant between-group differences
No sleep endpoint
Mitra 2024 [9]
Positive78 sedentary female college students (India)
500 or 1,000 mg/day, 30 days
Measured: Heart rate · VO2max · PWC170 · grip strength · mood scales
Found: Anxiety, depression, vitality, well-being improved at 1,000 mg
No sleep endpoint
Fatigue and mood are plausibly sleep-adjacent, but they are not sleep. None of these trials recorded sleep latency, sleep duration, sleep quality or any polysomnographic measure, and none enrolled patients with a diagnosis of insomnia. This is a summary of trial endpoints, not medical advice.
Human trial endpoints from refs [1][4][5][9] (see references)
Tang and colleagues (2005) ran the largest and most clearly positive of the four.[1] They randomized 132 Chinese patients diagnosed with neurasthenia — a traditional diagnostic category covering persistent fatigue, irritability, and poor concentration, which overlaps with but is not identical to insomnia. Patients received a Ganoderma lucidum polysaccharide extract (Ganopoly) at 1,800 mg three times a day for 8 weeks. Fatigue scores fell 28.3% from baseline versus 20.1% on placebo, and 51.6% of the reishi group rated themselves more than minimally improved versus 24.6% on placebo. The endpoints were Clinical Global Impression severity and visual analogue scales for fatigue and well-being. No sleep measure was taken.
Tang et al. (2005) · Journal of Medicinal Food
- Population
- 132 Chinese adults diagnosed with neurasthenia; 123 assessable at endpoint
- Intervention
- Ganoderma lucidum polysaccharide extract (Ganopoly), 1,800 mg three times daily — 5,400 mg/day total — for 8 weeks
- Comparator
- Matched placebo, randomized and double-blind
- Finding
- Fatigue severity fell 28.3% from baseline versus 20.1% on placebo; sense of well-being rose 38.7% versus 29.7%; 51.6% (32/62) rated more than minimally improved versus 24.6% (15/61) on placebo (p = .002).
positive Statistically significant on every prespecified measure, but all outcomes were self-reported and no sleep parameter was recorded. This is the source of the '1,800 mg' figure that circulates as a daily dose — it was a per-dose amount taken three times a day.
Tang et al., Journal of Medicinal Food, 2005 (ref 1)
Two trials come from the same Spanish research group working in fibromyalgia. Collado-Mateo and colleagues (2015) gave 64 women with fibromyalgia 6 g/day of Ganoderma lucidum for 6 weeks, against an active carob (Ceratonia siliqua) comparator rather than placebo.[4] Reishi significantly improved aerobic endurance, lower-body flexibility, and velocity. The endpoints were physical fitness tests.
Pazzi and colleagues (2020) then ran a double-blind, randomized, placebo-controlled pilot in women with fibromyalgia using 6 g/day of micro-milled reishi carpophores for 6 weeks.[5] This trial is frequently cited as evidence that reishi improves anxiety, depression, fatigue, and sleep-related quality of life. It did not show that. The published result is explicit: there were no statistically significant between-group differences. The authors reported a trend toward improved happiness and life satisfaction and reduced depression within the reishi group compared to its own baseline, and concluded that further studies were needed to confirm the findings.
Pazzi et al. (2020) · Healthcare (Basel)
- Population
- Women with fibromyalgia; double-blind randomized placebo pilot trial
- Intervention
- 6 g/day micro-milled Ganoderma lucidum carpophores (whole fruiting body, not an extract) for 6 weeks
- Comparator
- Matched placebo
- Finding
- No statistically significant between-group differences on happiness, depression, satisfaction with life, or health-related quality of life. A within-group trend toward improvement was observed in the reishi arm relative to its own baseline.
null A within-group trend in an unblinded comparison against baseline is the weakest form of positive signal, and the authors said so. The trial also used whole milled mushroom, not the standardized extract that consumer articles attribute to it.
Pazzi et al., Healthcare (Basel), 2020 (ref 5)
The fourth trial is Mitra and colleagues (2024), which is where several claims circulating about a "2024 reishi RCT" actually originate.[9] It is not a fibromyalgia trial. It enrolled 78 sedentary female college students in West Bengal, India, randomized to 500 mg/day, 1,000 mg/day, or placebo for 30 days. The 1,000 mg group showed significant improvements in heart rate, VO2max, physical work capacity, and grip strength versus placebo, along with significant improvements in anxiety, depression, vitality, and positive well-being scores. Sleep was not among the measured parameters.
Fact Check
The 1,800 mg/day reishi dose
The claim
“Clinical trials of reishi for sleep used approximately 1,800 mg per day of a standardized extract.”
A misreading of Tang et al. (2005), which dosed 1,800 mg three times a day. The per-dose figure gets repeated as a daily total, then attributed to trials that never used it.
What research shows
UnsupportedTang 2005 used 1,800 mg of Ganopoly extract three times daily, a total of 5,400 mg/day, in neurasthenia patients — not insomnia patients. The two fibromyalgia trials used 6 g/day of whole micro-milled mushroom, not an extract. Mitra 2024 used 500 or 1,000 mg/day. No human trial has used 1,800 mg/day as a total daily dose for any sleep outcome.
This matters commercially. A 1,800 mg/day target sits within reach of ordinary capsule products, whereas 5.4 g/day of concentrated extract or 6 g/day of milled mushroom does not. The misread figure makes consumer products look aligned with trial doses when they are roughly three to six times below them.
Tang et al., Journal of Medicinal Food, 2005 [ref 1]; Pazzi et al., Healthcare, 2020 [ref 5]; Mitra et al., Int J Med Mushrooms, 2024 [ref 9]
Provenance Audit
Where the “1,800 mg/day” Reishi Dose Actually Comes From
The figure is real, and it is in the literature. It is a per-dose amount from a neurasthenia trial, taken three times a day — a daily total of 5,400 mg. Repeated as a daily figure and attached to the fibromyalgia trials (which used 6 g/day of whole milled mushroom instead), it lands conveniently close to what a capsule can deliver.
The source
Tang 2005 dosed Ganopoly polysaccharide extract at 1,800 mg three times a day for 8 weeks in 132 patients with neurasthenia. Total: 5,400 mg/day.
The misreading
The per-dose figure is reported as a daily total, then attributed to the fibromyalgia trials — which used 6 g/day of whole micro-milled mushroom, not a standardised extract.
Why it matters
1,800 mg/day is reachable by a consumer capsule. 5,400 mg/day of concentrated extract is not. The misread number makes ordinary products look trial-aligned.
No trial in this chart measured a sleep outcome, so none of these doses is a validated sleep dose. They are shown to establish what was actually administered, not to recommend an amount. Rodent doses are excluded because milligram-per-kilogram animal exposures do not convert to human doses by body weight alone.
Dose provenance from refs [1][4][5][9][12] (see references)
The Rodent Sleep Data — and the Conditions Attached to It
The sleep-specific evidence for reishi is genuinely interesting. It is also entirely preclinical, and the conditions under which it was produced matter more than the headline results.
Chu and colleagues (2007) provided the most cited mechanistic finding.[2] The result usually quoted is that reishi extract decreased sleep latency and increased non-REM sleep. The sentence that usually gets dropped comes first in the same abstract: the extract showed no effects on sleep architecture in normal rats at 80 and 120 mg/kg. The positive effects appeared only in rats that had already been given pentobarbital. Flumazenil, a benzodiazepine-receptor antagonist, blocked those effects — which means reishi was acting through the benzodiazepine site on the GABA-A receptor, not through a separate one. The one effect flumazenil did not block was an increase in delta activity during non-REM sleep, suggesting at least one additional non-benzodiazepine pathway.
Cui and colleagues (2012) found a clearer effect without a sedative present.[3] Freely moving rats given 80 mg/kg of fruiting-body extract orally for three days showed increased total sleep time and increased NREM sleep, with no change to slow-wave or REM sleep. The mechanism here was not GABAergic at all: TNF-α rose in serum, hypothalamus, and dorsal raphe nucleus, and injecting a TNF-α antibody into the brain abolished the hypnotic effect. This is a cytokine-mediated route, not a receptor-mediated one.
Yao and colleagues (2021) identified a third mechanism entirely.[6] The acidic fraction of an alcohol extract of reishi mycelia, given to mice for 28 days, shortened sleep latency and prolonged sleeping time while raising hypothalamic serotonin. When the researchers depleted the gut microbiota with antibiotics, the sleep effect disappeared. Reishi was working through gut bacteria, not directly on the brain. This is the slower-developing pathway that plausibly explains why reishi is described as a compound that needs weeks rather than nights — and it is the mechanism covered in depth in how long does reishi take to improve sleep.
Qin and colleagues (2024) tested a sporoderm-removed spore extract at 720 mg/kg for 14 days in rats with an induced model of sporadic Alzheimer's disease.[11] It improved the model's reduced total, REM, and non-REM sleep time, apparently by suppressing NF-κB/NLRP3 neuroinflammation in the medial prefrontal cortex and restoring GABAergic activity in the parabrachial nucleus. A systems-pharmacology analysis by Qiu and colleagues (2021) reached a compatible conclusion from a different direction, identifying 34 candidate sedative-hypnotic components in Ganoderma acting largely through cytokine and apoptosis genes including TNF.[7]
Model Dependence
Reishi Did Nothing to a Normal Rat’s Sleep
The most consistently omitted line in the reishi sleep literature is the first sentence of the Chu 2007 results. Given acutely to an undrugged animal, reishi extract had no effect on sleep architecture at all. Every positive sleep finding in the corpus comes from one of two situations: a sedative was already on board, or the animal had been dosed for days to weeks.
| Study | Model condition | Dosing | Sleep outcome |
|---|---|---|---|
| Chu 2007 [2]Rats | Normal, undrugged | Acute, 80–120 mg/kg | No effect on sleep architectureGABA-A · benzodiazepine site |
| Chu 2007 [2]Rats | Pentobarbital on board | Acute | ↓ sleep latency, ↑ sleep time, ↑ non-REMGABA-A · benzodiazepine site (flumazenil-blocked) |
| Cui 2012 [3]Rats | Freely moving, no sedative | 80 mg/kg × 3 days | ↑ total sleep, ↑ NREM (REM unchanged)TNF-α cytokine signalling |
| Yao 2021 [6]Mice | Pentobarbital on board | 25–100 mg/kg × 28 days | ↓ latency, ↑ sleep time (abolished by antibiotics)Gut microbiota → serotonin |
| Qin 2024 [11]Rats | Sporadic Alzheimer's model | 720 mg/kg × 14 days | Restored total, REM and non-REM sleep timeNF-κB/NLRP3 ↓ · parabrachial GABA ↑ |
| Li 2024 [10]Mice | GBS blend (with G. sinense) | 14 days | Latency 6.8 → 4.2 min; duration 88 → 153 minNot resolved |
All findings above are from rats and mice. Milligram-per-kilogram animal doses do not convert to human doses by body weight alone, and no human trial has recorded any of these sleep parameters. The practical implication that survives translation is directional, not quantitative: in every model that has been run, reishi is not a take-it-tonight compound. This is a summary of preclinical findings, not medical advice.
Preclinical sleep findings from refs [2][3][6][10][11] (see references)
For the specific GABA and serotonin mechanisms underlying this profile, how reishi affects GABA and serotonin pathways covers the mechanistic detail, and how reishi improves sleep quality without sedation covers why these routes differ from sedative-hypnotic drugs.
- Cell & Network Analysiscompleted
Qiu 2021 systems pharmacology identified 34 candidate sedative-hypnotic components acting via TNF, CASP3, JUN, HSP90αA1
- Animal Sleep Studiescompleted
Chu 2007 (GABA-A/benzodiazepine site, pentobarbital model), Cui 2012 (TNF-α, freely moving rats), Yao 2021 (gut microbiota–serotonin, mice), Qin 2024 (Alzheimer model rats)
- Case Reportscompleted
Present for hepatotoxicity, not for sleep benefit
- Small Human Trials with a Sleep Endpointmissing
None. Four randomized human trials exist (Tang 2005, Collado-Mateo 2015, Pazzi 2020, Mitra 2024) and none measured sleep
- Large RCT in Diagnosed Insomniamissing
No randomized trial has enrolled patients with a diagnosis of insomnia
- Meta-Analysismissing
No sleep trials to pool
Reishi's sleep evidence stops at the animal tier. The mechanistic work is unusually good for a supplement — three distinct, independently supported pathways — but the ladder has a missing rung exactly where it matters, because the human trials that do exist measured fatigue, fitness and mood instead of sleep.
Assessment based on published trials and preclinical studies, 2005–2024
Dosing: What Was Actually Given
Because no trial has dosed reishi for a sleep outcome, there is no evidence-based sleep dose. What exists are doses that produced effects on adjacent outcomes, and they are considerably higher than what most products supply.
What the published human trials used:
- Ganopoly polysaccharide extract, 1,800 mg three times daily (5,400 mg/day), 8 weeks — Tang 2005, neurasthenia. The largest positive human trial, on fatigue and well-being.[1]
- Whole micro-milled fruiting body, 6 g/day, 6 weeks — Collado-Mateo 2015 (fitness, positive) and Pazzi 2020 (mood and quality of life, null).[4][5]
- Unspecified whole-mushroom preparation, 1,000 mg/day, 30 days — Mitra 2024, the lowest dose with a positive human result, on fitness and mood.[9]
- Extract, 2 g twice daily (4 g/day), 10 days — Wicks 2007, a dedicated safety and tolerability trial in 16 healthy adults, which found reishi well tolerated across ECG, blood count, blood chemistry, urinalysis, and immune-cell measures.[12]
Note that the direction most consumer articles assert — that the clinical evidence comes from standardized extracts rather than raw powder — is only half right, and backwards for the fibromyalgia trials specifically. Those used whole micro-milled mushroom. The extract evidence comes from the neurasthenia trial. Both forms have human data behind them; neither has sleep data behind it.
Dose Comparison
Reishi (Ganoderma lucidum), oral: Research vs. commercial doses
What research used
1,000 mg/day – 6 g/day
Oral
Daily, divided in the highest-dose trial · 10 days to 8 weeks across published trials
Tang 2005 used 5,400 mg/day of Ganopoly extract split into three doses; Collado-Mateo 2015 and Pazzi 2020 used 6 g/day of whole milled mushroom; Mitra 2024 used 1,000 mg/day. None of these trials measured sleep.
What supplements sell
250–1,000 mg/day
Oral
Daily, often a single capsule
Most reishi sleep capsules land at 500–1,000 mg, frequently as part of a multi-mushroom blend where reishi is only a fraction of the stated total.
The trial that produced the clearest positive human result used 5.4 g/day of concentrated extract — roughly five to twenty times a typical capsule dose. A 1,000 mg/day product matches only the Mitra 2024 arm, which measured fitness and mood, not sleep. There is no dose in this table that has been validated against a sleep outcome in humans.
- *1,800 mg was the per-dose amount in Tang 2005, taken three times daily. It is not a validated daily total.
- *Whole milled mushroom and concentrated polysaccharide extract are not interchangeable on a milligram basis.
- *No dose-response study for sleep has been published in any species at human-relevant exposures.
- *Rodent doses (80 mg/kg in Chu 2007 and Cui 2012, 720 mg/kg in Qin 2024) cannot be converted to human doses by body weight alone.
Tang et al. (2005); Collado-Mateo et al. (2015); Pazzi et al. (2020); Mitra et al. (2024); Wicks et al. (2007)
On timing
Taking reishi 1–3 hours before bed is a reasonable inference from the Chu 2007 benzodiazepine-site mechanism, which operates on an acute timescale. It is an inference, not a finding. No human trial has compared morning versus evening administration for any outcome, and the two mechanisms with the most consistent preclinical support — the TNF-α route and the gut-microbiota-serotonin route — both developed over days to weeks of repeated dosing rather than within a single evening. If reishi does anything for your sleep, the preclinical evidence suggests it is more likely to show up after several weeks of consistent use than on the first night.
Formulation: What the 2024 Recipe Study Actually Compared
The 2024 formulation research is frequently summarized as showing that hot-water extraction preserves more sleep-active compounds than other methods. That is not what it tested.
Li and colleagues (2024) compared two multi-ingredient recipes in mice over 14 days.[10] PGB combined reishi extract, broken reishi spore powder, and Paecilomyces hepiali mycelium. GBS combined reishi extract, broken spore powder, and Ganoderma sinense powder. The two recipes separated cleanly by outcome: PGB improved anti-fatigue performance, prolonging weight-bearing swim time from 10.1 to 15.2 minutes, while GBS improved sleep, shortening sleep latency from 6.8 to 4.2 minutes and extending sleep duration from 88.3 to 152.5 minutes.
The variable that changed was the companion ingredient, not the extraction solvent. Swapping Paecilomyces hepiali for Ganoderma sinense moved the effect from fatigue to sleep. This is a genuinely useful finding — it suggests reishi preparations are not interchangeable and that what is blended alongside reishi materially changes the outcome — but it says nothing about hot water versus alcohol, and it was measured in mice.
What can reasonably be said about product selection:
- Dose transparency matters more than extraction claims. The gap between a 500 mg capsule and the 5.4 g/day that produced Tang 2005's result is the largest single variable, and it is the one printed on the label.
- Single-species products let you know what you are taking. In a multi-mushroom blend, the reishi fraction is often unstated and small.
- Fruiting body versus grain-grown mycelium changes composition — grain substrate contributes starch that counts toward product weight — though no sleep trial has compared them.
- Broken or sporoderm-removed spore preparations are more bioavailable than intact spores, a point the 2023 systematic review does support.[8]
For a broader look at how triterpene and polysaccharide content differ across products, reishi and depression: mood regulation evidence covers a closely related application. For the historical clinical context behind the neurasthenia trial, Ganoderma lucidum and neurasthenia covers that evidence base in depth.
Safety: The Part the Reviews Do Not Call Reassuring
Reishi is often described as having a well-established safety profile with no serious adverse events. The primary source usually cited for that claim says something more cautious.
Thuy and colleagues (2023) systematically reviewed 90 studies of Ganoderma lucidum spores.[8] The pharmacological effects it documents are anti-tumor, anti-inflammatory, antioxidant, and immunomodulatory. Sedative and hypnotic activity are not among the effects the review establishes. On safety, its conclusion was that reishi safety "should be investigated in depth," because high doses of spore extract increased levels of the cancer antigen CA72-4, and it recommended that high doses be used with caution. That is a flag, not a clearance.
Against that, Wicks and colleagues (2007) ran a dedicated double-blind placebo-controlled safety trial in 16 healthy adults taking 4 g/day for 10 days and found no significant adverse effects.[12] Sixteen people for ten days is reassuring about short-term tolerability and silent about months of daily use, which is what a sleep supplement actually implies.
The case-report literature fills in the rest. Wanmuang and colleagues (2007) documented a fatal fulminant hepatitis associated with Ganoderma lucidum mushroom powder in a patient who had previously tolerated traditionally boiled Lingzhi without incident.[13] Guedikian and colleagues (2023) reported reishi-induced acute liver injury in the setting of alcohol use, with recovery on supportive care.[14] Two case reports cannot establish incidence. They do establish that the outcome is possible, and both point at powdered preparations rather than decoctions.
Hepatotoxicity
CriticalReishi powder has been linked to serious liver injury, including one death
Concern
Wanmuang and colleagues reported a fatal case of fulminant hepatitis in a patient taking Ganoderma lucidum (Lingzhi) mushroom powder. Notably, the patient had previously taken traditionally boiled Lingzhi without toxicity, and the hepatotoxic episode began after switching to the powdered form. Guedikian and colleagues later reported acute liver injury with significant transaminitis in a patient consuming reishi alongside alcohol; he recovered with supportive care. Separately, the 2023 systematic review of reishi spores found high doses raised the cancer antigen CA72-4 and advised caution.
What the research says
Case reports cannot establish how often reishi causes liver injury. They do establish that it can. The preparation-specific pattern — powder implicated, decoction tolerated — and the alcohol co-ingestion case are both consistent with the wider picture of unregulated supplements varying in composition and contamination.
Particularly relevant for: Anyone using reishi daily long-term, and especially people who drink alcohol regularly, take hepatotoxic or sedative medications, are pregnant or breastfeeding, or have existing liver disease
What to do
Treat reishi as a substance with a real documented hepatic signal, not a benign botanical. Do not combine it with heavy alcohol use, and seek medical evaluation for abdominal pain, dark urine, or jaundice.
Wanmuang et al., J Med Assoc Thai, 2007 (ref 13); Guedikian et al., Cureus, 2023 (ref 14); Thuy et al., Cureus, 2023 (ref 8)
Before You Try It
ModerateThis article describes research, not a treatment plan
Concern
Chronic insomnia is a diagnosable condition with effective first-line treatment — cognitive behavioural therapy for insomnia has stronger evidence than any supplement discussed here. Persistent sleep disruption can also be the presenting sign of sleep apnoea, thyroid disease, depression, or a medication side effect, none of which a mushroom will address. Reishi's preclinical mechanism runs partly through the benzodiazepine site of the GABA-A receptor, which is the same site targeted by prescription sedatives.
What the research says
Nothing here is a recommendation to treat, prevent, or cure any condition, and no dose in this article has been validated against a sleep outcome in humans. Use it to understand what the research does and does not show.
Particularly relevant for: People taking sedatives, benzodiazepines, Z-drugs, anticoagulants, immunosuppressants, or diabetes medication; people who are pregnant or breastfeeding; anyone with a liver condition or upcoming surgery
What to do
Talk to a qualified healthcare provider before starting reishi, particularly alongside prescription medication, and see a clinician about insomnia that has lasted more than three months.
Chu et al. (2007); Thuy et al. (2023); general pharmacovigilance guidance
The Bottom Line
Reishi has four randomized controlled human trials and none of them measured sleep. The strongest is Tang et al. (2005), which gave 132 neurasthenia patients a polysaccharide extract at 1,800 mg three times daily — 5,400 mg/day — for 8 weeks and found significant improvements in fatigue and well-being. The widely repeated "1,800 mg/day" dosing figure is that per-dose amount misread as a daily total. The 2020 placebo-controlled fibromyalgia pilot used 6 g/day of whole milled mushroom and returned a null result. All sleep-specific findings are preclinical, and heavily model-dependent: reishi extract did nothing to sleep architecture in normal rats and only worked once a sedative was already on board, though repeated dosing produced effects through separate TNF-α and gut-microbiota-serotonin routes. The 2023 spore systematic review did not establish sedative activity and flagged a CA72-4 elevation at high doses. Reishi powder carries a documented hepatotoxicity signal including one fatality. The mechanistic case for reishi and sleep is unusually well developed for a supplement; the human case has not been tested.
Frequently Asked Questions
Sources & References
- 1RTHM-00088·Tang, Wenbo et al. (2005). “A randomized, double-blind and placebo-controlled study of a Ganoderma lucidum polysaccharide extract in neurasthenia..” Journal of medicinal food.Study breakdown →PubMed →↩
- 2RTHM-00210·Chu, Qing-Ping et al. (2007). “Extract of Ganoderma lucidum potentiates pentobarbital-induced sleep via a GABAergic mechanism..” Pharmacology.Study breakdown →PubMed →↩
- 3RTHM-00458·Cui, Xiang-Yu et al. (2012). “Extract of Ganoderma lucidum prolongs sleep time in rats..” Journal of ethnopharmacology.Study breakdown →PubMed →↩
- 4RTHM-00679·Collado Mateo, Daniel et al. (2015). “GANODERMA LUCIDUM IMPROVES PHYSICAL FITNESS IN WOMEN WITH FIBROMYALGIA..” Nutricion hospitalaria.Study breakdown →PubMed →↩
- 5RTHM-00648·Pazzi, Francesco et al. (2020). “Ganoderma lucidum Effects on Mood and Health-Related Quality of Life in Women with Fibromyalgia..” Healthcare (Basel.Study breakdown →PubMed →↩
- 6RTHM-00731·Yao, Chunyan et al. (2021). “Ganoderma lucidum promotes sleep through a gut microbiota-dependent and serotonin-involved pathway in mice..” Scientific reports.Study breakdown →PubMed →↩
- 7RTHM-01419·Qiu, Yu et al. (2021). “Exploration of the anti-insomnia mechanism of Ganoderma by central-peripheral multi-level interaction network analysis..” BMC microbiology.Study breakdown →PubMed →↩
- 8RTHM-01802·Thuy, Nguyen Huu Lac et al. (2023). “Pharmacological Activities and Safety of Ganoderma lucidum Spores: A Systematic Review..” Cureus.Study breakdown →PubMed →↩
- 9RTHM-00895·Mitra, Sudeep et al. (2024). “Efficacy of Lingzhi or Reishi Medicinal Mushroom Ganoderma lucidum (Agaricomycetes) Supplementation on Psychological Stress and Selective Fitness Profile Parameters in Female College Students in West Bengal, India..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
- 10RTHM-01928·Li, Kexin et al. (2024). “The anti-fatigue and sleep-aiding effects vary significantly among different recipes containing Ganoderma lucidum extracts..” Heliyon.Study breakdown →PubMed →↩
- 11RTHM-01970·Qin, Yu et al. (2024). “Ganoderma lucidum spore extract improves sleep disturbances in a rat model of sporadic Alzheimer's disease..” Frontiers in pharmacology.Study breakdown →PubMed →↩
- 12RTHM-00123·Wicks, Sheila M et al. (2007). “Safety and tolerability of Ganoderma lucidum in healthy subjects: a double-blind randomized placebo-controlled trial..” The American journal of Chinese medicine.Study breakdown →PubMed →↩
- 13RTHM-00122·Wanmuang, Harirak et al. (2007). “Fatal fulminant hepatitis associated with Ganoderma lucidum (Lingzhi) mushroom powder..” Journal of the Medical Association of Thailand = Chotmaihet thangphaet.Study breakdown →PubMed →↩
- 14RTHM-00826·Guedikian, Roupen et al. (2023). “Ganoderma lingzhi (Reishi Mushroom)-Induced Acute Liver Injury in the Setting of Alcohol Use: A Case Report and Review of the Literature..” Cureus.Study breakdown →PubMed →↩